** Medical equipment maker TransMedics' TMDX.O shares rise 4.4% to $75 premarket
** Co's Q4 revenue of $121.6 million beats analysts' average expectation of $110.3 million, according to data compiled by LSEG
** TMDX forecasts annual revenue between $530 mln and $552 mln, the midpoint of which is above analysts' average estimate of $539 mln - LSEG
** Up to last close, stock down 18.7% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。